Monopar Therapeutics appoints Susan Rodriguez as CCSO

Monopar Therapeutics (MNPR) announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company’s commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application to the U.S. Food and Drug Administration in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson disease. She most recently served as COO of Avadel Pharmaceuticals (AVDL).